Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

MEDIQON Group AG (CHG) Price & Analysis

CHG Stock Chart & Stats

€45.75-€2.90(-5.96%)
At close: 4:00 PM EDT
EUR 40EUR 453 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 45.60 - EUR 48.20
52-Week Range
EUR 25.10 - EUR 49.65
Previous Close
EUR 48.65
Volume
11.23K
Average Volume (3M)
24.56K
Market Cap
EUR 1.16B
Enterprise Value
EUR 1.19B
Total Cash (Recent Filing)
EUR 115.41M
Total Debt (Recent Filing)
EUR 265.58M
Price to Earnings (P/E)
―
Beta
0.26
Next Earnings
May 27, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Revenue growth has remained a clear business strength, with 2025 sales increasing about 37% to approximately 181m. This indicates strong market expansion and product or service demand, providing a broader base from which management can pursue operating leverage and improve future profitability.

Positive Cash Generation

Consistently positive operating and free cash flow gives the company an important source of internal funding despite reported losses. Continued cash generation can support operations, investment, and debt servicing, reducing reliance on external financing if this performance remains sustainable.

Substantial Equity Cushion

The sizeable equity base and asset base provide a meaningful financial cushion for the business. Although leverage has increased materially, this underlying balance-sheet scale can help absorb operating volatility and preserve flexibility while management addresses the company’s profitability challenges.

Bears Say

Severe Profitability Deterioration

The sharp reversal from a normal gross-profit level in 2024 to negative gross profit and large operating and net losses shows that revenue scale is not currently translating into earnings. Persistent losses could weaken reinvestment capacity and make recovery dependent on substantial cost or operational improvements.

Material Leverage Increase

The dramatic increase in debt materially changes the company’s financial risk profile, especially alongside deeply negative earnings. Higher leverage can raise debt-servicing demands and reduce flexibility to fund growth or withstand further operating weakness, making balance-sheet repair an important medium-term priority.

Free Cash Flow Decline

Free cash flow remains positive but declined substantially in 2025, while the company also reports sizable accounting losses. A sustained reduction in cash generation would make it harder to support investment and service the heavier debt burden, increasing the importance of restoring stronger cash conversion.

CHG FAQ

What was MEDIQON Group AG’s price range in the past 12 months?
MEDIQON Group AG lowest stock price was €25.10 and its highest was €49.65 in the past 12 months.
What is MEDIQON Group AG’s market cap?
MEDIQON Group AG’s market cap is €1.16B.
When is MEDIQON Group AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MEDIQON Group AG’s earnings last quarter?
MEDIQON Group AG released its earnings results on Oct 09, 2026. The company reported -€0.887 earnings per share for the quarter.
Is MEDIQON Group AG overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does MEDIQON Group AG pay dividends?
MEDIQON Group AG does not currently pay dividends.
What is MEDIQON Group AG’s EPS estimate?
MEDIQON Group AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDIQON Group AG have?
MEDIQON Group AG has 25,364,090 shares outstanding.
What happened to MEDIQON Group AG’s price movement after its last earnings report?
MEDIQON Group AG reported an EPS of -€0.887 in its last earnings report. Following the earnings report the stock price went down -0.119%.
Which hedge fund is a major shareholder of MEDIQON Group AG?
Currently, no hedge funds are holding shares in DE:CHG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology